Altimmune ALT
NASDAQ ALT
$1.93 -0.01 (-0.52%)
At close: Nov 11, 2026 · 4:00 PM EST

Altimmune (ALT) Short-Term Debt repayments (2013 - 2014)

Updated

Analysis

Altimmune (ALT) Short-Term Debt repayments (2013 - 2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 6.63 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Altimmune 377.28 Mn -764.94 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 -1.09 Mn
Dec 31, 2013 1.09 Mn
Sep 30, 2013 -1.17 Mn
API Access

Altimmune Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=ALT&period=max&api_key=YOUR_API_KEY